Despite recent findings by Arrowhead Pharmaceuticals suggesting that finite treatment with an RNAi medicine might be possible in the sear...

Today, Ionis issued a press release  revelaing that their drug candidate for Huntington’s Disease was able to knock down the huntingtin ta...

When Arrowhead suffered its DPC fiasco a year ago, it got a chance to re-prioritize its pipeline.  It therefore caught my attention that d...

In the final instalment of the stock market-focused mini-series, I will turn my attention to the non-RNAi Oligonucleotide Therapeutics sec...

Having covered the most developed RNAi companies (Alnylam, Arrowhead, Dicerna) yesterday, this blog entry will discuss RNAi plays that are...

According to the RNAi calendar, a calendar characterized by 3-year sentiment cycles, we are coming to the end of the first third of anothe...

It’s not every day that you can see a person like chess playing legend Gary Kasparov at a biotech company’s Investors Day.   And if you did...